Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Noberasco

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Tumori|December 31, 1994
Formestane as treatment of advanced breast cancer in elderly womenN Zilembo, R Buzzoni, L Celio, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Formestane: an effective first-line endocrine treatment for advanced breast cancerN Zilembo, E Bajetta, C Noberasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Formestane: effective therapy in postmenopausal women with advanced breast cancerE Bajetta, N Zilembo, R Buzzoni, et al.
British Journal of Cancer|July 1, 1994
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancerE Bajetta, N Zilembo, R Buzzoni, et al.
Breast Cancer Research and Treatment|January 1, 1994
Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancerL Ferrari, N Zilembo, E Bajetta, et al.
British Journal of Cancer|October 1, 1995
Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitorN Zilembo, C Noberasco, E Bajetta, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Pre-operative chemotherapy and radiotherapy in breast cancerM Colleoni, F Nole, I Minchella, et al.
International Journal of Oncology|April 30, 2011
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancerL Ferrari, E Bajetta, E Seregni, et al.
Psycho-Oncology|October 15, 2013
The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory studyC Catania, D Radice, G Spitaleri, et al.
Journal of Cancer Research and Clinical Oncology|November 20, 2012
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumoursG Spitaleri, R Berardi, C Pierantoni, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Tumori|December 31, 1994
Formestane as treatment of advanced breast cancer in elderly womenN Zilembo, R Buzzoni, L Celio, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Formestane: an effective first-line endocrine treatment for advanced breast cancerN Zilembo, E Bajetta, C Noberasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Formestane: effective therapy in postmenopausal women with advanced breast cancerE Bajetta, N Zilembo, R Buzzoni, et al.
British Journal of Cancer|July 1, 1994
Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancerE Bajetta, N Zilembo, R Buzzoni, et al.
Breast Cancer Research and Treatment|January 1, 1994
Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancerL Ferrari, N Zilembo, E Bajetta, et al.
British Journal of Cancer|October 1, 1995
Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitorN Zilembo, C Noberasco, E Bajetta, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Pre-operative chemotherapy and radiotherapy in breast cancerM Colleoni, F Nole, I Minchella, et al.
International Journal of Oncology|April 30, 2011
Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancerL Ferrari, E Bajetta, E Seregni, et al.
Psycho-Oncology|October 15, 2013
The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory studyC Catania, D Radice, G Spitaleri, et al.
Journal of Cancer Research and Clinical Oncology|November 20, 2012
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumoursG Spitaleri, R Berardi, C Pierantoni, et al.
Pageof 4